title: Reduced nerve injury-induced neuropathic pain in kinin B1 receptor knock-out mice.
abstract: Injury to peripheral nerves often results in a persistent neuropathic pain condition that is characterized by spontaneous pain, allodynia, and hyperalgesia. Nerve injury is accompanied by a local inflammatory reaction in which nerve-associated and immune cells release several pronociceptive mediators. Kinin B1 receptors are rarely expressed in nontraumatized tissues, but they can be expressed after tissue injury. Because B1 receptors mediate chronic inflammatory painful processes, we studied their participation in neuropathic pain using receptor gene-deleted mice. In the absence of neuropathy, we found no difference in the paw-withdrawal responses to thermal or mechanical stimulation between B1 receptor knock-out mice and 129/J wild-type mice. Partial ligation of the sciatic nerve in the wild-type mouse produced a profound and long-lasting decrease in thermal and mechanical thresholds in the paw ipsilateral to nerve lesion. Threshold changed neither in the sham-operated animals nor in the paw contralateral to lesion. Ablation of the gene for the B1 receptor resulted in a significant reduction in early stages of mechanical allodynia and thermal hyperalgesia. Furthermore, systemic treatment with the B1 selective receptor antagonist des-Arg9-[Leu8]-bradykinin reduced the established mechanical allodynia observed 7-28 d after nerve lesion in wild-type mice. Partial sciatic nerve ligation induced an upregulation in B1 receptor mRNA in ipsilateral paw, sciatic nerve, and spinal cord of wild-type mice. Together, kinin B1 receptor activation seems to be essential to neuropathic pain development, suggesting that an oral-selective B1 receptor antagonist might have therapeutic potential in the management of chronic pain.
authors.affiliation: Department of Pharmacology, Centre of Biological Sciences, Universidade Federal de Santa Catarina, 88015-420 Florianópolis, Brazil. ferreiraj99@bol.com.br
authors.forename: Juliano
authors.initials: J
authors.lastname: Ferreira
authors.forename: Alessandra
authors.initials: A
authors.lastname: Beirith
authors.forename: Marcelo A S
authors.initials: MA
authors.lastname: Mori
authors.forename: Ronaldo C
authors.initials: RC
authors.lastname: Araújo
authors.forename: Michael
authors.initials: M
authors.lastname: Bader
authors.forename: João B
authors.initials: JB
authors.lastname: Pesquero
authors.forename: João B
authors.initials: JB
authors.lastname: Calixto
mesh_terms: D000818:Animals; D001920:Bradykinin / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D065169:Bradykinin B1 Receptor Antagonists; D005260:Female; D007839:Functional Laterality; D015870:Gene Expression / Q000502:physiology; D006930:Hyperalgesia / Q000235:genetics / Q000503:physiopathology; D008297:Male; D051379:Mice; D018345:Mice, Knockout / Q000502:physiology; D009437:Neuralgia / Q000209:etiology* / Q000628:therapy; D010147:Pain Measurement / Q000379:methods; D012333:RNA, Messenger / Q000378:metabolism; D043783:Receptor, Bradykinin B1 / Q000172:deficiency* / Q000235:genetics / Q000502:physiology*; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000379:methods; D020426:Sciatic Neuropathy / Q000150:complications*; D012867:Skin / Q000378:metabolism / Q000473:pathology; D012881:Skin Temperature / Q000235:genetics; D013997:Time Factors
chemical_list: D065169:Bradykinin B1 Receptor Antagonists; D012333:RNA, Messenger; D043783:Receptor, Bradykinin B1; C024626:bradykinin, des-Arg(9)-; C051090:bradykinin, Leu(8)-des-Arg(9)-; D001920:Bradykinin
references.citation: Lancet. 1999 May 8;353(9164):1610-5
references.pmid: 10334274
references.citation: Lancet. 1999 Jun 5;353(9168):1959-64
references.pmid: 10371588
references.citation: Proc Natl Acad Sci U S A. 1999 Jul 6;96(14):7737-8
references.pmid: 10393890
references.citation: Pain. 1999 Dec;83(3):487-97
references.pmid: 10568857
references.citation: Pain. 2000 Jun;86(3):265-71
references.pmid: 10812256
references.citation: Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):8140-5
references.pmid: 10859349
references.citation: Pain. 2000 Jul;87(1):1-5
references.pmid: 10863040
references.citation: Neurosci Lett. 2000 Nov 24;294(3):175-8
references.pmid: 11072143
references.citation: Neuroreport. 2000 Dec 18;11(18):4003-5
references.pmid: 11192618
references.citation: Nat Rev Neurosci. 2001 Feb;2(2):83-91
references.pmid: 11252998
references.citation: Exp Neurol. 2001 Jun;169(2):386-91
references.pmid: 11358451
references.citation: Neuroreport. 2001 Aug 8;12(11):2311-4
references.pmid: 11496101
references.citation: Nature. 2001 Sep 13;413(6852):203-10
references.pmid: 11557989
references.citation: Eur J Pharmacol. 2001 Oct 19;429(1-3):161-76
references.pmid: 11698039
references.citation: Neuroscience. 2001;107(4):665-73
references.pmid: 11720789
references.citation: Neuropharmacology. 2001 Dec;41(8):1006-12
references.pmid: 11747905
references.citation: Pain. 2002 Sep;99(1-2):175-84
references.pmid: 12237195
references.citation: Eur J Pharmacol. 2002 Dec 20;457(2-3):115-24
references.pmid: 12464357
references.citation: Neuropharmacology. 2002 Dec;43(7):1188-97
references.pmid: 12504926
references.citation: Neuropeptides. 2003 Feb;37(1):36-44
references.pmid: 12637034
references.citation: J Comp Neurol. 2003 Jul 7;461(4):506-19
references.pmid: 12746865
references.citation: Inflamm Res. 2003 Apr;52(4):164-9
references.pmid: 12755382
references.citation: Nat Rev Drug Discov. 2003 Jun;2(6):460-72
references.pmid: 12776221
references.citation: Pain. 2003 Aug;104(3):683-91
references.pmid: 12927641
references.citation: J Comp Neurol. 2003 Oct 20;465(3):372-84
references.pmid: 12966562
references.citation: Peptides. 2003 Aug;24(8):1131-9
references.pmid: 14612183
references.citation: J Pharmacol Exp Ther. 2004 Mar;308(3):1158-64
references.pmid: 14634040
references.citation: J Pharmacol Exp Ther. 2004 May;309(2):661-9
references.pmid: 14747609
references.citation: Br J Pharmacol. 2004 Mar;141(5):787-94
references.pmid: 14967737
references.citation: Brain Res. 2004 Apr 23;1006(1):114-25
references.pmid: 15047030
references.citation: Br J Pharmacol. 2004 Dec;143(7):803-18
references.pmid: 15520046
references.citation: Pain. 1991 Sep;46(3):299-313
references.pmid: 1661885
references.citation: Pain. 1991 Jun;45(3):309-20
references.pmid: 1876441
references.citation: Pain. 1990 Nov;43(2):205-18
references.pmid: 1982347
references.citation: Neurosci Lett. 1990 Jul 17;115(1):62-7
references.pmid: 2216058
references.citation: Pain. 1988 Jan;32(1):77-88
references.pmid: 3340425
references.citation: Pain. 1983 Jun;16(2):109-10
references.pmid: 6877845
references.citation: Br J Pharmacol. 1995 May;115(2):368-72
references.pmid: 7670739
references.citation: J Biol Chem. 1995 Jun 9;270(23):13706-10
references.pmid: 7775424
references.citation: Neurosci Lett. 1994 May 23;173(1-2):5-8
references.pmid: 7936422
references.citation: Neuroscience. 1995 Nov;69(2):685-90
references.pmid: 8552260
references.citation: Inflamm Res. 1995 Oct;44(10):407-11
references.pmid: 8564515
references.citation: Exp Neurol. 1996 Sep;141(1):94-101
references.pmid: 8797671
references.citation: Neuropharmacology. 1997 Jul;36(7):1009-17
references.pmid: 9257945
references.citation: Neuroscience. 1998 Apr;83(3):949-59
references.pmid: 9483576
references.citation: Brain Res. 1998 Jun 29;797(2):243-54
references.pmid: 9666140
references.citation: Pain. 1998 May;76(1-2):215-22
references.pmid: 9696476
references.citation: Pharmacol Rev. 1998 Sep;50(3):357-86
references.pmid: 9755287
references.citation: Acta Orthop Belg. 1998 Dec;64(4):448-51
references.pmid: 9922551